Iqvia Holdings provides contract research, commercial services and data analytics to pharmaceutical and biotech companies, a set of services that matter when drug developers outsource clinical trials and commercial launches. The company has a market capitalization near $45.2 billion and sits inside the Life Science Tools & CDMO theme, where scale, client relationships and data assets are competitive advantages.
Revenue has moved from roughly $3.73 billion in mid-2023 quarters to $4.15 billion in CY2026Q1, and the most recent quarter showed an 8.41% year-over-year revenue gain. Growth has been steady rather than accelerating, and GAAP diluted EPS has been volatile across quarters; the latest reported GAAP diluted EPS was $1.61 in CY2026Q1, a 15% year-over-year increase after several quarters with declines or smaller gains.
The business sits with traits of theme leadership: six of seven trend checks pass, relative strength versus the S&P is strong (about +37% excess return over 12 months), institutional ownership covers roughly 1.03% of the float across 1,559 reporting institutions, and accumulation signals are positive. Those factors support the stock’s Stage-2 continuation status while the fundamental picture remains steady growth with episodic EPS swings.
Why now
Recent quarterly results show a renewed top-line pickup, with CY2026Q1 revenue up 8.41% year over year and GAAP diluted EPS up 15%, while the stock sits near its 52-week high and has outperformed the S&P noticeably over 3- and 12-month windows.
The setup
The price closed at $270.97 on 2026-09-28, above the 50-day average ($248.89) and the 200-day average ($205.02), with the 9-day EMA at $269.51 and the 21-day EMA at $264.71, leaving the share price roughly 0.5% above the 9-day EMA. RSI is moderate at 61.11 and the 50-day up/down volume ratio is 1.33, indicating net accumulation. The technical picture qualifies as a Stage-2 continuation, but there is no fresh verified breakout or 9/21-day EMA add setup and one trend test remains unmet because the 150-day moving average has not climbed above the 200-day moving average.
Revenue trajectory
Full-year revenue with year-over-year growth. Solid bars are calendar-year actuals from SEC EDGAR filings (XBRL); dashed bars are analyst consensus via Yahoo Finance (18 analysts), which is published two fiscal years out.Earnings trajectory
Solid bars are quarterly GAAP diluted EPS from SEC EDGAR filings. Dashed bars are analyst consensus, which is typically adjusted (non-GAAP). The two are measured differently, so a step between the last actual and the first estimate usually reflects that change in basis rather than a change in the business.Analyst full-year EPS consensus (typically adjusted): FY'26E $12.97 (+9%) · FY'27E $14.46 (+12%) — 18 analysts
Risks
Revenue acceleration is not established and growth could decelerate if pharma R&D spending softens or large clients shift contracts. GAAP diluted EPS has been volatile, with several quarters showing year-over-year declines, introducing earnings unpredictability. A high valuation implicit in a large-market-cap services franchise leaves less margin for execution errors or guidance disappointments.
Framework fit
CANSLIM
5/7- CCurrent quarterly GAAP EPS growth ≥ 25%+15%✕
- AAnnual GAAP EPS growth ≥ 25%+5%✕
- NNew highs — within 15% of 52-week high-1.47%✓
- SSupply/demand — up-day volume leads1.33x✓
- LLeader — outperforming the S&P 500+45% 6m✓
- IInstitutional sponsorshipmodel score 7/10✓
- MMarket in a confirmed uptrendConfirmed uptrend✓
Minervini Trend Template
6/7Stage 2 confirmation checklist: price versus rising long-term moving averages and the 52-week range.
Weinstein Stage
Established uptrend: price is above a rising 30-week proxy, with the 200-day line used as a separate confirmation.